Roche Showcases Solutions for Laboratories of the Future at the Association for Diagnostics & Laboratory Medicine 2024 Clinical Lab Expo
Roche will present its growing portfolio of integrated systems and data solutions to optimize your resources and simplify and streamline your lab operations to drive better health outcomes
INDIANAPOLIS and CHICAGO — July 25, 2024 — Roche (SIX: RO, ROG; OTCQX: RHHBY) will showcase a laboratory of the future exhibit at the 2024 Association for Diagnostics & Laboratory Medicine (ADLM) Scientific Meeting and Clinical Lab Expo, July 28 through August 1 in Chicago. Attendees will have the opportunity to experience how Roche's growing portfolio of integrated systems and data solutions optimizes resources and simplifies and streamlines operations while driving better health outcomes.
Focusing on key attributes of science-based leadership, operational simplicity and patient-centric partnership, Roche will feature its newest innovations in-booth at ADLM, including:
- The future cobas® Mass Spec solution* is a total end-to-end solution for clinical mass spectrometry testing with the goal of seamless integration into the routine laboratory.
- The new CCM Vertical is a flexible modular system that uses lab space effectively and seamlessly integrates into the existing cobas® connection modules.
- The cobas® liat system brings gold-standard PCR technology to the point of care, providing results within 20 minutes across a growing menu of assays, now including the cobas liat SARS-CoV-2, Influenza A/B & RSV assay** to test for four common respiratory viruses, all in within one test.
- The cobas® pure integrated solutions combine clinical chemistry, immunoassay, and ion-selective electrode (ISE) diagnostic testing on a single platform for low- to mid-volume testing needs.
- The cobas® eplex system, a rapid syndromic molecular diagnostic solution, has been updated with new features across all aspects of the workflow process.
- The cobas® 5800 is a compact, fully automated molecular PCR-testing solution with a comprehensive menu of assays.
- The LightCycler® PRO is a qPCR system designed to deliver accuracy and flexibility to research and clinical diagnostic laboratories with an improved user experience.
Roche also will present its full array of navify® digital solutions, which securely integrate data across care settings, connecting the healthcare community and accelerating access to innovation and insights. Our digital solutions enable confident healthcare decisions and help you drive operational, clinical, and financial value.
With the largest diagnostics installed base worldwide, Roche provides unrivaled ability to scale access to testing at speed for those who need it most. The cobas® reagent portfolio offers the broadest menu on an integrated platform and includes the Elecsys® Alzheimer's cerebrospinal fluid (CSF) assays, aiming to more effectively detect and support an Alzheimer’s diagnosis.
Roche will also present eight Roche Idea Lab segments in booth 2003, where experts will discuss topics such as mass spectrometry, digital solutions, respiratory testing, and the use of high-medical-value assays when treating Alzheimer’s and heart failure.
Scientific industry workshops will include “Laboratorians’ Perspectives on Evaluation and Implementation of Alzheimer’s CSF Assays” and “Making a Subjective Sepsis Diagnosis More Objective: The Role of AI-based Sepsis Medical Algorithms in Empowering Healthcare Decisions.”
For more information about Roche’s participation at ADLM 2024 and Roche Idea Lab programming, visit ADLM.roche.com.
Featured Roche Idea Lab sessions include:
Tuesday, July 30
Improving Access and Patient Outcomes for Sexually Transmitted Infections | 11 a.m. CST
This session will delve into innovative strategies for enhancing patient access to STI testing and shed light on the promising potential of these approaches to positively impact public health outcomes.
Speakers: Barbara Van Der Pol, PhD, MPH, University of Alabama at Birmingham, and Casey Pinto, PhD, NP, Penn State University
Moving Beyond the Transactional Operation with navify® Digital Solutions to Unlock New Possibilities for Better Care | 2:30 p.m. CST
This session will explore how navify® cutting-edge algorithms help move beyond transactional operations to foster a holistic approach for better care with AI.
Speaker: Peter McCaffrey, MD, University of Texas
Testing for Heart Failure in People with Diabetes—What Do the New ADA Guidelines Mean for Labs? | 3:30 p.m. CST
This session will discuss how to put the American Diabetes Association recommendation for heart failure risk monitoring in all people with diabetes into practice.
Speaker: Ibrahim A. Hashim, MSc, PhD, CSci, FIBMS, DABCC, FAACC, UT Southwestern Medical Center, Parkland Hospital and Health System
Wednesday, July 31
Advancing Respiratory Testing Across the Continuum of Care | 10:30 a.m. CST
This session will discuss how strategies to improve diagnostic stewardship for respiratory infections contribute to better patient care.
Speakers: David Gaston, MD, PhD, and Alisha Ezell, MHA, MLS(ASCP)CM, Vanderbilt Health
Making Patient Impact with Ions: A Conversation on the Medical Value of Mass Spectrometry | 1 p.m. CST
This session will feature a conversation on the medical value of mass spectrometry and provide specific case examples related to patient outcomes.
Speaker: Victoria Zhang, PhD, MBA, DABCC, University of Rochester Medical Center
The Pathway to Growing Your Lab | 2:30 p.m. CST
This session will share ideas on how labs can remain competitive by utilizing existing capacity and improving access for patients in support of optimized clinical care.
Speakers: Steve Serota and Robin Herbner, Wisconsin Diagnostic Laboratories
Are You Listening? The Black Pregnant Woman's Instincts and Preeclampsia | 3:30 p.m. CST
This session will discuss the Black woman's experience with healthcare and the role diagnostics can play in improving outcomes for preeclampsia patients.
Speaker: Sarosh Rana, MD, MPH, FACOG, University of Chicago Medicine
Current and Future Biomarker Testing Landscape in Alzheimer's Disease | 4:15 p.m. CST
This session will discuss how the availability of Alzheimer's biomarkers in CSF and blood is revolutionizing the diagnostic path.
Speaker: Leslie Shaw, PhD, University of Pennsylvania
*Not currently for sale in the United States.
**This product has not been cleared or approved by the Food and Drug Administration (FDA), but has been authorized for emergency use by the FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories.